MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

Vaccines are designed to guard babies, toddlers, and older children against a whole range of serious and potentially deadly ...

Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...

A social media post claims that Moderna’s CEO confessed to creating a COVID vaccine before the pandemic. After fact checking, we found that the claim is false. According to an Instagram post, “Moderna ...

Moderna has previously announced deals to build research units in Australia and Canada since its coffers were swelled by COVID-19 vaccine sales, and has also said it is planning to build a $500 ...

Karen Andersen, CFA, is a healthcare strategist for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She is r ...

Moderna Inc. reported a wider-than-expected fourth-quarter loss on Wednesday, as the biotech company grapples with declining COVID-19 vaccine sales and ongoing restructuring costs. The vaccine maker ...

Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million. It is the first time that Merck has ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare industry ...

Disinformation campaigns targeting the Quad, a partnership between Australia, India, Japan, and the United States, challenge ...

Nasdaq 100, S&P 500, Dow Jones Industrial Average, Cisco Systems Inc. Read Investing.com (Jesse Cohen)'s latest article on ...